News

February 14, 2018

Biogen Releases Statement on CHERISH Data and Plans for New Clinical Research

Biogen Releases Statement on CHERISH Data and Plans for New Clinical Research

Biogen has provided the following community statement on the final results from CHERISH, a Phase 3 study of SPINRAZA. 

Dear Members of the SMA community,

This past December marked one year since the FDA approval of SPINRAZA® (nusinersen), the first and only treatment...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

February 1, 2018

AveXis Releases Community Statement on STR1VE

AveXis Releases Community Statement on STR1VE

AveXis has provided the following community statement on AVXS-101.

Dear SMA Community,

AveXis, the gene therapy company developing a new approach to treat SMA known as AVXS‐101, is pleased to initiate screening for the remaining patients to be enrolled in the pivotal trial of...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

January 30, 2018

Preliminary Data from FIREFISH Trial in Type 1 SMA Infants Presented at the International Scientific Congress on Spinal Muscular Atrophy

PTC Therapeutics, Inc. recently announced the presentation of early interim data from Part 1, the dose-finding portion of the FIREFISH study. FIREFISH is a two-part seamless, open-label, multi-center study to investigate the safety and efficacy of RG7916 in infants and babies with Type 1 SMA. RG7916 has been safe and well tolerated at all...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

Items 1 - 3 of 109  12345678910Next

© 2018 Cure SMA | Privacy Policy

Powered by Blackbaud
nonprofit software